Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Commun Biol. 2020 May 7;3(1):219. doi: 10.1038/s42003-020-0952-y.
Prolonged treatment of immunocompromised influenza patients with viral neuraminidase (NA) inhibitors is required, because the immune system of such patients fails to eradicate the viruses. Here, we attempted to eradicate influenza virus from the respiratory organs of nude mice, which is a model of immunocompromised hosts, by using combination therapy of the viral polymerase inhibitor favipiravir and monoclonal antibodies (mAbs) against the receptor-binding site (RBS) and stem of viral hemagglutinin (HA). Although monotherapy or combination therapy of two antivirals (two mAbs or favipiravir plus a mAb) suppressed virus replication, they failed to eradicate viruses from nude mice. In contrast, the triple combination therapy of favipiravir plus anti-Stem and anti-RBS mAbs completely stopped virus replication in nude mice, resulting in virus clearance. Triple combination approaches should be considered for the treatment of human immunocompromised patients with severe influenza.
免疫功能低下的流感患者需要长期接受病毒神经氨酸酶 (NA) 抑制剂治疗,因为此类患者的免疫系统无法清除病毒。在这里,我们尝试通过使用聚合酶抑制剂法匹拉韦联合针对受体结合位点 (RBS) 和血凝素 (HA) 茎部的单克隆抗体 (mAb) 的联合疗法,从免疫功能低下宿主模型——裸鼠的呼吸道中清除流感病毒。尽管抗病毒药物单药治疗或联合治疗(两种 mAb 或两种抗病毒药物联合一种 mAb)可抑制病毒复制,但无法从裸鼠中清除病毒。相比之下,法匹拉韦联合抗-Stem 和抗-RBS mAb 的三联疗法可完全抑制裸鼠中的病毒复制,从而清除病毒。三联疗法可能需要考虑用于治疗人类免疫功能低下的严重流感患者。